Sign In
Buy LPTX
$0.690
+0 (+0%)
At Close: Jun 23, 2026
Apellis (APLS) Expands Deal for Targeted Complement Therapies
03:55pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Apellis (APLS) expands its current research and development deal with privately held company, Affilogic, to develop targeted complement therapies for delivery into the brain.
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
04:26pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.
Bristol Myers' (BMY) Breyanzi sBLA Receives EMA Validation
02:32pm, Tuesday, 21'st Jun 2022 Zacks Investment Research
The EMA validates Bristol Myers' (BMY) type II variation application for the label expansion of Breyanzi for treating relapsed/refractory large B-cell lymphoma after first-line therapy.
Seagen (SGEN) Stock Up on Rumors of Acquisition by Merck
04:19pm, Monday, 20'th Jun 2022 Zacks Investment Research
Shares of Seagen (SGEN) rise after rumors of a buyout by Merck hit the market. However, a deal is not imminent at the moment.
FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid
03:27pm, Monday, 20'th Jun 2022 Zacks Investment Research
An FDA advisory committee votes against Acadia's (ACAD) Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis.
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study
03:52pm, Friday, 17'th Jun 2022 Zacks Investment Research
Addex (ADXN) terminates the phase IIb/III study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease. Shares fall.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
03:16pm, Friday, 17'th Jun 2022 Zacks Investment Research
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA
02:42pm, Thursday, 16'th Jun 2022 Zacks Investment Research
The FDA issues briefing documents related to Acadia's (ACAD) resubmitted sNDA for Nuplazid for treating hallucinations and delusions associated with Alzheimer's disease psychosis. Shares rise.
Deciphera (DCPH) Up More Than 30% in Past 3 Months: Here's Why
03:10pm, Wednesday, 15'th Jun 2022 Zacks Investment Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Alnylam's (ALNY) Rare Disease Drug, Amvuttra, Gets FDA Nod
03:12pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
The FDA approves Alnylam's (ALNY) Amvuttra (vutrisiran) to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development
04:01pm, Monday, 13'th Jun 2022 Zacks Investment Research
Immunovant (IMVT) remains focused on developing lead pipeline candidate, batoclimab for treating several types of autoimmune diseases. Lack of other pipeline candidate remains a concern.
Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study
02:51pm, Friday, 10'th Jun 2022 Zacks Investment Research
Alnylam (ALNY) reports top-line data from a phase II study evaluating its investigational RNAi therapeutic, cemdisiran, for the treatment of immunoglobulin A nephropathy.
Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED
02:48pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Immunovant's (IMVT) earnings miss estimates in fiscal fourth quarter ended on Mar 31, 2022. The company achieves FDA alignment for phase III study on batoclimab in thyroid eye disease.
Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease
02:14pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.
Praxis (PRAX) Tanks on Negative Data From Depression Study
03:30pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.
